Miklos Gaszner, M.D., Ph.D.

Shareholder

Miklos Gaszner combines a deep understanding of biosciences and patent law to build strong patent portfolios for his clients.

Nixon Vanderhye Shareholder Miklos Gaszner, M.D., Ph.D., advises biotechnology and pharmaceutical companies on the development and execution of global patent strategy. He is skilled in U.S. and international patent procurement, invalidity, non-infringement, and patentability opinions, as well as freedom-to-operate and due diligence investigations.

Miklos has deep technical experience in the following areas:

Therapeutic Antibodies, including antibody engineering, production, and formulation
Cancer Treatment, including immuno oncology therapies and cancer vaccines
HIV Vaccines
RNA-Based Therapeutics, including antisense RNAs and therapeutic mRNAs
Recombinant Microorganisms
Metabolic Engineering
Influenza Vaccines
Food Supplements

Prior to entering private practice, Miklos worked in-house as a patent agent at MedImmune LLC (now part of AstraZeneca), and was most recently a director at a prominent intellectual property law firm based in Washington, D.C.

Miklos received a Ph.D. in Molecular Biology from Princeton University. His research focused on chromatin structure and eukaryotic transcriptional control.

Practices

Patents
- Preparation and Prosecution
- Post-Grant Proceedings
- Due Diligence
- Domestic and Worldwide Portfolio Management
- PTAB Practice
- Opinions & Counseling
IP Transactions, Agreements, and Trade Secrets
- Licensing, Sales, and Assignments
- Non-Disclosure Agreements
- Due Diligence

Industries

Biotechnology
- Therapeutic
  - Therapy
    - Protein based therapeutics
      
      Biotherapeutics (biologics and biosimilars)
      
      Antibody based drugs
      
      Antibody mimetics
      
      Peptide drugs
      
      Vaccines
    - Nucleic acid based therapeutics
      
      RNA and RNA analogue therapeutics
      
      DNA and DNA analogue therapeutics
      
      Gene therapy
      
      Genome editing
    - Cell based therapeutics
      
      Tissue engineering and regeneration
      
      Cell engineering
      
      Immune therapeutics
      
      Microbiome based therapeutics
    - Stem cell, progenitor, and primary cell therapeutics
    - Regenerative therapeutics
    - Targeted therapeutics
    - Drug discovery, delivery, and formulation platforms
  - Manufacturing
    - Upstream bioprocessing (cell culture, bioreactor and fermentation technology)
    - Downstream bioprocessing (purification)
    - Formulation
  - Diagnostics
    - Protein based diagnostics technologies
    - Nucleic acid based diagnostics
    - Precision medicine
    - Theranostics
    - Pharmacogenomics
    - Companion diagnostics
  - Medical devices
- Industrial and Agricultural Biotechnology
  - Synthetic biology
  - Protein engineering
  - Biocatalysts (enzymes and microorganisms)
  - Bioprocessing (bioreactor and fermentation technology)
  - Plant and microorganism metabolic engineering
  - Genetically modified organisms (microorganisms, plants, and animals)
  - Bio based products (chemicals, monomers, polymers, and gasses)
  - Green and clean technology
- Nutraceuticals
Pharmaceuticals
- New Chemical Entities
  - Synthetic compounds
  - Natural products and derivatives
- Drug Repositioning
  - Prodrugs
  - Combinations
  - New indications
  - New pharmacokinetics
  - Targeted drug delivery
  - Precision medicine
- Manufacturing
  - Synthetic chemistry
  - Polymorphs and co-crystals
  - Purification
  - Formulation
- Drug Discovery and development tools
  - Combinatory chemistry
  - Drug screening assays
  - Drug design platforms
  - Catalysis and reactors
Chemical, Industrial & Material Science
- Food and beverages
  - Dietary supplements
  - Food additives
- Nanotechnology
- Polymers
- 3-D Printing
- Organometallics
- Cosmetics
- Herbicides and pesticides
- Analytical chemistry
- Ceramics

Bar Admissions

Maryland
District of Columbia
U.S. Patent and Trademark Office

Education

J.D., magna cum laude, American University, Washington College of Law, 2011
Ph.D. in Molecular Biology, Princeton University, 1999
M.D., summa cum laude, Albert Szent-Gyorgyi Medical University, Hungary, 1992

Publications

Co-Author, “Patenting the Plant Microbiome,” Industrial Biotechnology, pp.123-125, 2018.
Co-Author, “Are Your Claims Patent Eligible?” Biofuels International, pp. 52-54, July/August 2015.
Co-Author, “Inter Partes Review - One Year Later,” Euro Biotech News, p. 14, 2014.
Co-Author, “Insulators: Exploiting Transcriptional and Epigenetic Mechanisms,” Nature Reviews Genetics, pp. 703-713, September 2006.
Co-Author, “Recruitment of Histone Modifications by USF proteins at a Vertebrate Barrier Element,” Molecular Cell, pp. 453-463, Nov. 5, 2004.
Co-Author, “Correlation Between Histone Lysine Methylation and Developmental Changes at the Chicken Beta-Globin Locus,” Science, pp. 2453-2455, Sept. 28, 2001.